ABIVAX To Participate in the Upcoming RBC Capital Markets 2016 Healthcare Conference in New York, and in the Credit Suisse Healthcare Conference in London

PARIS--()--Regulatory News:

ABIVAX (Paris:ABVX) (Euronext Paris: FR0012333284 – ABVX), an emerging leader in developing and commercializing anti-viral drugs and therapeutic vaccines for diseases like HIV/AIDS and chronic hepatitis B (CHB), today announced that its CEO, Prof. Hartmut Ehrlich, M.D., will participate in the RBC Capital Markets 2016 Healthcare Conference in New York on February 23rd and 24th, and in the Credit Suisse Healthcare Conference in London on March 1st and 2nd.

At the RBC Capital Markets 2016 Healthcare conference, Prof. Ehrlich is scheduled to participate in a fireside chat with RBCCM healthcare analyst Douglas Miehm at 8:30 AM (EST) on February 23rd. This conversation will be webcast, and will be available on ABIVAX’s website. Additionally, Prof. Ehrlich and ABIVAX’s CFO, Alain Chevallier, will conduct one-on-one meetings with interested investors over the course of the conference.

At the Credit Suisse Healthcare conference in London, Prof. Ehrlich and Mr. Chevallier will meet with investors in one-on-one meetings over the course of the conference.

ABIVAX (www.abivax.com) is an emerging global leader in the discovery, development and commercialization of anti-viral therapeutics and vaccines to treat some of the world’s most life-threatening infectious diseases, including HIV/AIDS and chronic Hepatitis B. ABIVAX has 2 compounds in clinical stage research: ABX464 a novel first-in-class resistance-proof oral small molecule HIV/AIDS therapy; and, ABX203, a therapeutic vaccine that could cure chronic Hepatitis B. ABIVAX also is advancing additional anti-viral compounds and therapeutic vaccines that may enter the clinical stage in the coming 18 months.
Follow us on Twitter @ABIVAX_

Contacts

ABIVAX
Investor relations
Raquel Lizarraga, +33 1 53 83 09 63
raquel.lizarraga@abivax.com
or
Citigate Dewe Rogerson
Lucie Larguier, +33 1 53 32 84 75
abivax@citigate.fr
or
Press relations
ALIZE RP
Caroline Carmagnol and Florence Portejoie, +33 6 64 18 99 59 / + 33 1 44 54 36 64
abivax@alizerp.com
or
LifeSci Advisors
Chris Maggos, +41 79 367 6254
chris@lifesciadvisors.com

Contacts

ABIVAX
Investor relations
Raquel Lizarraga, +33 1 53 83 09 63
raquel.lizarraga@abivax.com
or
Citigate Dewe Rogerson
Lucie Larguier, +33 1 53 32 84 75
abivax@citigate.fr
or
Press relations
ALIZE RP
Caroline Carmagnol and Florence Portejoie, +33 6 64 18 99 59 / + 33 1 44 54 36 64
abivax@alizerp.com
or
LifeSci Advisors
Chris Maggos, +41 79 367 6254
chris@lifesciadvisors.com